Epizyme Emerges From Stealth Mode
This article was originally published in The Pink Sheet Daily
Executive Summary
Tiny start-up aims to be a dominant player in the unfolding field of epigenetics.
You may also be interested in...
Eisai Deal Puts Epizyme In Position To Advance Lead Program
Deal with Eisai on epigenetic enzymes is collaborative, whereas in recent tie up with GSK, Epizyme gave up control of development and commercialization of select histone methyltransferases.
Eisai Deal Puts Epizyme In Position To Advance Lead Program
Deal with Eisai on epigenetic enzymes is collaborative, whereas in recent tie up with GSK, Epizyme gave up control of development and commercialization of select histone methyltransferases.
Genentech Exec Heads East To Take The Reins Of Cancer-Focused Start-up Agios
Calling it “the right time and the right opportunity,” Genentech’s cancer drug development expert David Schenkein plans to move on.